TRILACICLIB DECREASES MULTI-LINEAGE MYELOSUPPRESSION IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) PATIENTS RECEIVING 1ST LINE CHEMOTHERAPY

K.H. Davis...

BACKGROUND

Only one event (trilaciclib arm) may have been influenced by hematologic toxicity.

STUDY OBJECTIVES

STUDY DESIGN

PART 1 RESULTS

PART 2 RESULTS

CONCLUSIONS

TRILACICLIB)...